Treatment for skin psoriasis
S.I.S is a bio-pharmaceutical company focused on the research and development of novel human therapeutics. S.I.S has identified, isolated and synthesized a group of a novel non-toxic four amino acid long peptides aimed at anti- viral, painkillers and skin disorders therapy, such as in psoriasis (US patent granted).
S.I.S products are effective exclusively upon topical application and are formulated as cream..
The company's two lead products coded Zep-3 and Zep-4, were assessed for their safety and efficacy in several pre-clinical in-vitro, ex-vivo and in-vivo studies. In addition to their analgesics activity, Zep-3 cream demonstrated an anti-viral activity in those pre-clinical studies, inhibiting the replication and spreading of Herpes Simplex Virus Type 1 (HSV1) in a dose dependent fashion without any detectable adverse side effects. Currently, Zep-3 cream is in Phase I clinical study while Zep-4 cream is at final stages of development as anti Psoriasis therapy.
After concluding the Phase I clinical study (Q3, 2013) we will initiate a Phase II study for HSV1 Cold Sores indication and a Phase II study for the Genital Herpes indication
Psoriasis is a chronic skin disease that is the most prevalent autoimmune disease in the U.S., with as many as 7.5 million Americans affected (2.45% of the population). It occurs when the immune system mistakes the skin cells as a pathogen, and sends out faulty signals that speed up the growth cycle of skin cells.